Repositioning Candidate Details
| Candidate ID: | R1029 |
| Source ID: | DB06492 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Mirococept |
| Synonyms: | Mirococept |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Mirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI. It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation. It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the naturally occurring membrane-bound myristoyl-electrostatic switch peptide. |
| CAS Number: | 507453-82-9 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in transplant (rejection), kidney disease, and rheumatoid arthritis. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Mirococept comprises the C3/C5 convertase-inhibiting region of CR1. This complement inhibitory domains of CR1 (in APT070) contain C3b-binding sites that lead to dissociation and inactivation of C3b from the classical and alternative pathway convertases. Mirococept effectively blocks and reduces the generation of the activated form of C3, and thwarts the release of both C3a and C5a. |
| Targets: | Complement C3 |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |